Skip to content

INTELLIPHARMACEUTICS INTERNATIONAL INC.: 20-F filed 2019-03-04

What INTELLIPHARMACEUTICS INTERNATIONAL INC. reported in its annual report (foreign private issuer) filed 2019-03-04 (fiscal FY 2018): 33 published measures, 88 facts as tagged in accession 0001654954-19-002210.

This filing

Form
20-F (annual report (foreign private issuer))
Filed
2019-03-04
Fiscal period
fiscal FY 2018
Accession
0001654954-19-002210 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; a measure with a published history links to it, and the history shows the latest-filed value per period. All INTELLIPHARMACEUTICS INTERNATIONAL INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2018-11-3011,474,227CAD
At 2017-11-307,396,781CAD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2018-11-307,371,920CAD
At 2017-11-307,010,398CAD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2018-11-304,102,307CAD
At 2017-11-30386,383CAD
At 2016-11-301,116,264CAD
At 2015-11-30-137,686CAD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2018-11-306,641,877CAD
At 2017-11-301,897,061CAD
At 2016-11-304,144,424CAD
At 2015-11-301,755,196CAD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2017-12-01 to 2018-11-30-13,747,480CAD365
2016-12-01 to 2017-11-30-8,857,440CAD365
2015-12-01 to 2016-11-30-10,143,577CAD366

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2017-12-01 to 2018-11-30101,178CAD365
2016-12-01 to 2017-11-301,823,746CAD365
2015-12-01 to 2016-11-30515,410CAD366

Revenue

Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.

PeriodValueUnitDays
2017-12-01 to 2018-11-301,712,731CAD365
2016-12-01 to 2017-11-305,504,452CAD365
2015-12-01 to 2016-11-302,247,002CAD366

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2018-11-30-85,620,939CAD
At 2017-11-30-71,873,459CAD

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2017-12-01 to 2018-11-300CAD365
2016-12-01 to 2017-11-300CAD365
2015-12-01 to 2016-11-300CAD366

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2018-11-302,755,993CAD
At 2017-11-303,267,551CAD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2017-12-01 to 2018-11-30927,686CAD365
2016-12-01 to 2017-11-301,749,999CAD365
2015-12-01 to 2016-11-302,261,444CAD366

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2017-12-01 to 2018-11-30-13,326,266CAD365
2016-12-01 to 2017-11-30-8,265,782CAD365
2015-12-01 to 2016-11-30-9,851,076CAD366

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2018-11-308,718,234CAD
At 2017-11-303,563,928CAD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2017-12-01 to 2018-11-30255,231CAD365
2016-12-01 to 2017-11-30389,239CAD365
2015-12-01 to 2016-11-30270,238CAD366

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2018-11-305,309,420CAD
At 2017-11-304,647,898CAD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2018-11-302,643,437CAD
At 2017-11-302,060,084CAD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2018-11-30239,063CAD
At 2017-11-30689,619CAD

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2018-11-30251,651CAD
At 2017-11-30115,667CAD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2017-12-01 to 2018-11-301,587,861CAD365
2016-12-01 to 2017-11-304,800,446CAD365
2015-12-01 to 2016-11-302,247,002CAD366

Selling, general and administrative expense

Selling and general administrative costs reported under this concept. It is an expense category, not a substitute for total operating expenses.

PeriodValueUnitDays
2017-12-01 to 2018-11-303,476,450CAD365
2016-12-01 to 2017-11-303,287,914CAD365
2015-12-01 to 2016-11-303,546,132CAD366

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2017-12-01 to 2018-11-3010,827,293CAD365
2016-12-01 to 2017-11-309,271,353CAD365
2015-12-01 to 2016-11-308,166,736CAD366

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2018-11-3018,252,243shares
At 2017-11-303,470,451shares
At 2016-11-3029,789,992shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2018-11-3045,110,873CAD
At 2017-11-3036,685,387CAD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

PeriodValueUnitDays
At 2018-11-30284,421CAD
At 2017-11-30284,421CAD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2018-11-308,041,498CAD
At 2017-11-307,940,320CAD
At 2016-11-306,041,569CAD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2018-11-305,285,505CAD
At 2017-11-304,672,769CAD
At 2016-11-304,151,931CAD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2018-11-30353,147CAD
At 2017-11-30782,369CAD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2018-11-30586,794CAD
At 2017-11-30225,092CAD

Net deferred tax assets

Deferred tax assets after the valuation allowance. Realization depends on future taxable income, so the balance is not a receivable from tax authorities.

PeriodValueUnitDays
At 2018-11-300CAD
At 2017-11-300CAD
At 2016-11-300CAD

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2017-12-01 to 2018-11-30612,736CAD365
2016-12-01 to 2017-11-30520,838CAD365
2015-12-01 to 2016-11-30385,210CAD366

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2017-12-01 to 2018-11-30209,675CAD365
2016-12-01 to 2017-11-30123,204CAD365
2015-12-01 to 2016-11-30165,585CAD366

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2017-12-01 to 2018-11-30-450,556CAD365
2016-12-01 to 2017-11-30283,994CAD365
2015-12-01 to 2016-11-30-6,200CAD366

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2017-12-01 to 2018-11-30135,984CAD365
2016-12-01 to 2017-11-30115,667CAD365
2015-12-01 to 2016-11-300CAD366

Inspect the source

Entity
INTELLIPHARMACEUTICS INTERNATIONAL INC. / CIK 0001474835
Captured
SEC response SHA-256
b43bbafa3486320e53e47da45874c043f53139ec0b74aaba3fa200c8a1927667

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001474835.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))